Cyclerion Therapeutics Inc
Cyclerion Therapeutics, Inc., a biopharmaceutical company, develops treatments for serious diseases serious diseases with novel sGC stimulators in both the central nervous system (CNS) and the periphery. It is developing Olinciguat, an orally administered vascular soluble guanylate cyclase (sGC) stimulator, which is in Phase 2 clinical trial to treat cardiovascular diseases; and Praliciguat, a sy… Read more
Cyclerion Therapeutics Inc (CYCN) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: -0.028x
Based on the latest financial reports, Cyclerion Therapeutics Inc (CYCN) has a cash flow conversion efficiency ratio of -0.028x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-264.00K) by net assets ($9.54 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cyclerion Therapeutics Inc - Cash Flow Conversion Efficiency Trend (2016–2024)
This chart illustrates how Cyclerion Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Cyclerion Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Cyclerion Therapeutics Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Tempest Security AB
ST:TSEC
|
0.596x |
|
Reneuco Berhad
KLSE:7130
|
0.003x |
|
Jet Freight Logistics Limited
NSE:JETFREIGHT
|
0.076x |
|
CN Energy Group Inc
NASDAQ:CNEY
|
-0.005x |
|
Wave Entertainment Public Company Limited
BK:WAVE
|
-0.006x |
|
Mirae JSC
VN:KMR
|
N/A |
|
Verici Dx plc
PINK:VRCDF
|
-1.497x |
|
NSN Co. Ltd
KQ:031860
|
-0.027x |
Annual Cash Flow Conversion Efficiency for Cyclerion Therapeutics Inc (2016–2024)
The table below shows the annual cash flow conversion efficiency of Cyclerion Therapeutics Inc from 2016 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $8.85 Million | $-4.33 Million | -0.490x | +73.99% |
| 2023-12-31 | $11.29 Million | $-21.25 Million | -1.882x | +51.56% |
| 2022-12-31 | $10.45 Million | $-40.61 Million | -3.885x | -413.35% |
| 2021-12-31 | $48.25 Million | $-36.52 Million | -0.757x | +37.88% |
| 2020-12-31 | $59.49 Million | $-72.49 Million | -1.218x | -16.50% |
| 2019-12-31 | $97.73 Million | $-102.22 Million | -1.046x | -111.20% |
| 2018-12-31 | $-10.45 Million | $-97.50 Million | 9.335x | -1.53% |
| 2017-12-31 | $-8.57 Million | $-81.22 Million | 9.480x | +28.52% |
| 2016-12-31 | $-6.76 Million | $-49.87 Million | 7.377x | -- |